Bavarian Nordic has inked a deal with the EU's newly-established European Health Emergency Preparedness and Response Authority (HERA) to supply 110,000 doses of MVA-BN smallpox/monkeypox vaccine, as the multi-nation monkeypox outbreak continues.
The vaccines will be made available to EU Member States, Norway and Iceland. Doses are to be delivered in proportion to the population, starting with states with the most urgent needs.
As of June 10, 2022, the CDC reported over 1400 confirmed monkeypox cases in 33 countries that are not endemic to the monkeypox virus. The UK, Spain, Portugal and Germany have reported the highest number of cases.
Bavarian Nordic's vaccine, MVA-BN — known as Imvanex in Europe and Jynneos in the U.S. — is a non-replicating smallpox vaccine developed in collaboration with the U.S. government. The U.S. FDA approved the vaccine for both smallpox and monkeypox in 2019, but it is not yet authorized in the EU against monkeypox.
Back in May, the Danish biotech announced a $119 million order for Jynneos placed by the U.S. government, with the option to buy $180 million more if needed.